Journal Home > Volume 15 , Issue 5

Smart drug delivery nanosystem is significant for tumor treatments due to its possibility of temporally, spatially, and dose-controlled release. However, the therapeutic efficacy of drug delivery nanosystem is often compromised in cancer treatment as the enrichment of therapeutic agents in the reticuloendothelial system. Herein, doxorubicin (DOX) loaded biomimetic drug delivery nanosystem with macrophage cell membrane (MCM) camouflaged, MnFe2O4-DOX-MCM nanocube (NC), is developed for cancer treatment with tumor targeting, pH-stimuli drug release, and chemo-photothermal therapeutic effects. The nanosystem shows the capability of immune escape and enhanced cellular uptake of cancer cells due to the MCM decoration. Acid-labile bond between the MnFe2O4 NCs and DOX remains stable at physiological condition and release drugs immediately in response to the endo-/lysosome pH stimuli. Meanwhile, the photothermal effect of the nanosystem destroys tumor tissue, which further promotes chemotherapeutic efficacy. In vivo results demonstrate the tumor homing ability and produce a notable synergistic therapeutic effect of the NCs. Thus, biomimetic pH-responsive drug delivery nanosystem, MnFe2O4-DOX-MCM NCs, is an effective nanoplatform, which might be potential application for cancer synergistic treatment.

File
12274_2022_4077_MOESM1_ESM.pdf (1.3 MB)
Publication history
Copyright
Acknowledgements

Publication history

Received: 08 October 2021
Revised: 29 November 2021
Accepted: 17 December 2021
Published: 08 February 2022
Issue date: May 2022

Copyright

© Tsinghua University Press 2022

Acknowledgements

Acknowledgements

This work was financially supported by the National Natural Science Foundation of China (Nos. 52027801, 51631001, and 52002402), the National Key R&D Program of China (No. 2017YFA0206301) the Natural Science Foundation of Beijing Municipality (No. 2191001), and the China-German Collaboration Project (No. M-0199), and the Natural Science Foundation of Jiangsu Province (No. BK20200574). The animal study protocol was approved by the Institutional Animal Care and Use Committee at Peking University.

Return